Milestone Asset Management LLC Has $211,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Milestone Asset Management LLC lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 76.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 684 shares of the biotechnology company's stock after selling 2,190 shares during the quarter. Milestone Asset Management LLC's holdings in United Therapeutics were worth $211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock worth $68,422,000 after acquiring an additional 221,202 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in United Therapeutics by 15.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company's stock worth $1,991,000 after acquiring an additional 769 shares during the period. NorthCrest Asset Manangement LLC boosted its position in United Therapeutics by 1.5% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,598 shares of the biotechnology company's stock worth $1,975,000 after acquiring an additional 84 shares during the period. Lansforsakringar Fondforvaltning AB publ acquired a new position in United Therapeutics during the 4th quarter worth $4,778,000. Finally, Siemens Fonds Invest GmbH acquired a new position in United Therapeutics during the 4th quarter worth $162,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,500 shares of company stock worth $16,923,950. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $0.23 during trading hours on Wednesday, hitting $323.97. 390,841 shares of the company's stock traded hands, compared to its average volume of 440,270. The firm has a market cap of $14.61 billion, a P/E ratio of 14.23, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a twelve month low of $266.98 and a twelve month high of $417.82. The stock's fifty day moving average price is $300.11 and its two-hundred day moving average price is $334.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.17 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on UTHR. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Cantor Fitzgerald began coverage on United Therapeutics in a research note on Monday. They issued an "overweight" rating and a $405.00 price objective on the stock. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research note on Monday, April 21st. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $393.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.